Skip to main content

Table 1 Clinical characteristics of subject at baseline

From: Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study

 

Semaglutide group

(n = 24)

DPPI inhibitors group (n = 27)

p value

Age (years)

65.6 ± 11.1

66.7 ± 9.9

0.714

Sex, male, n (%)

13 (54.2)

15 (55.6)

0.921

Body weight (kg)

67.9 ± 12.7

65.1 ± 12.0

0.420

Body mass index (kg/m2)

26.2 ± 3.0

25.0 ± 3.4

0.193

Duration of diabetes (years)

13.7 ± 6.0

14.4 ± 8.9

0.947

Hypertension, n (%)

13 (54.2)

15 (55.6)

0.921

Dyslipidemia, n (%)

19 (79.2)

23 (85.2)

0.718

Blood pressure (mm Hg)

   

Systolic

131.5 ± 17.8

130.6 ± 14.6

0.843

Diastolic

75.1 ± 9.2

73.1 ± 11.3

0.847

HDL-C (mg/dL)

55.2 ± 12.3

56.7 ± 11.6

0.658

LDL-C (mg/dL)

94.9 ± 16.2

96.3 ± 21.0

0.789

Triglyceride (mg/dL)

117.0 (93.5–205.0)

110.0 (83.0–183.0)

0.365

AST(GOT) (IU/L)

20.5 (17.3–26.8)

19.0 (16.0–28.0)

0.545

ALT(GPT) (IU/L)

24.0 (16.0–36.8)

21.0 (15.0–36.0)

0.533

γ-GTP (IU/L)

28.0 (20.4–41.5)

29.0 (20.0–58.0)

0.947

eGFR (ml/min/1.73 m2)

74.1 ± 21.4

69.7 ± 15.5

0.397

UACR (mg/g Cre)

22.9 (10.6–53.9)

25.0 (8.6–47.1)

0.828

FPG (mg/dL)

144.6 ± 27.0

149.0 ± 24.7

0.549

HbA1c (%)

7.6 ± 0.4

7.6 ± 0.4

0.956

Mean glucose level (mg/dL)

157.1 ± 21.8

159.4 ± 18.2

0.679

Markers of glucose variability

   

SD (mg/dL)

40.1 ± 6.9

39.8 ± 8.5

0.706

MAGE (mg/dL)

105.4 ± 26.9

99.9 ± 20.8

0.411

MODD (mg/dL)

34.0 ± 7.8

34.0 ± 8.0

0.938

%CV (mg/dL)

25.9 ± 5.4

25.0 ± 4.7

0.512

Time above range (%)

28.3 ± 15.4

28.3 ± 14.1

0.995

Time in range (%)

70.6 ± 14.5

71.6 ± 14.1

0.807

Time below range (%)

0.0 (0.0–0.0)

0.0 (0.0–0.0)

0.743

d-ROMs (U.CARR)

348.5 ± 73.1

362.1 ± 93.8

0.858

Macroangiopathy

1 (4.2)

6 (22.2)

0.103

Neuropathy

8 (33.3)

9 (33.3)

1.000

Nephropathy

12 (50.0)

10 (37.0)

0.351

Retinopathy

8 (33.3)

11 (40.7)

0.585

Antidiabetic drugs

   

Sulfonylureas, n (%)

4 (16.7)

6 (22.2)

0.731

Glinides, n (%)

2 (8.3)

1 (3.7)

0.595

Thiazolidine, n (%)

6 (25.0)

1 (3.7)

0.042

α-glucosidase inhibitors, n (%)

2 (8.3)

5 (18.5)

0.425

Metformin, n (%)

21 (87.5)

21 (77.8)

0.473

SGLT2 inhibitors, n (%)

19 (79.2)

17 (63.0)

0.205

DPP4 inhibitors

   

Sitagliptin (50 mg/day)

3 (12.5)

4 (14.8)

 

Linagliptin (5 mg/day)

12 (50.0)

15 (55.6)

 

Alogliptin (25 mg/day)

5 (27.8)

3 (11.1)

 

Vildagliptin (100 mg/day)

1 (4.2)

4 (14.8)

 

Anagliptin (200 mg/day)

1 (4.2)

0 (0.0)

 

Teneligliptin (20 mg/day)

2 (8.3)

1 (3.7)

 

Antihypertensive drugs

   

ARBs or ACEs, n (%)

10 (41.7)

14 (51.9)

0.467

Calcium channel blockers, n (%)

6 (25.0)

9 (33.3)

0.514

Diuretics, n (%)

1 (4.2)

0 (0.0)

0.471

α-blockers, n (%)

1 (4.2)

0 (0.0)

0.471

β-blockers, n (%)

0 (0.0)

1 (3.7)

1.0000

Antihyperlipidemic drugs

   

Statins, n (%)

16 (66.7)

21 (77.8)

0.375

Fibrates, n (%)

2 (11.1)

2 (7.4)

1.000

Ezetimibe, n (%)

0 (0.0)

2 (7.4)

0.492

DTSQ score

n = 20

n = 20

 

Treatment satisfaction

24.4 ± 4.9

24.2 ± 5.2

0.926

Frequency of hyperglycemia and

hypoglycemia

4.4 ± 2.0

4.2 ± 2.6

0.784

  1. Data are expressed as mean ± standard deviation, medians (interquartile ranges), or numbers (%)
  2. HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, eGFR Estimated glomerular filtration rate, FPG Fasting plasma glucose, HbA1c Hemoglobin A1c, SD Standard deviation, MAGE Mean amplitude of glycemic excursions, MODD Mean of daily difference of blood glucose, %CV Percentage coefficient of variation for glucose d-ROMs Diacron-reactive oxygen metabolites, 1 U.CARR (arbitrary unit) = The oxidant capacity of a 0.08 mg/dL H2O2 solution, SGLT Sodium glucose cotransporter, DPP-4 Dipeptidyl peptidase 4, ARB Angiotensin II receptor blocker, ACE Angiotensin-converting enzyme inhibitor, DTSQ Diabetes treatment satisfaction questionnaire
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us